CliniGA CRO

CliniGA CRO Blog

Discussing How to Report Other Medicines and Products

A participant may not fully understand which medicines or products the study team wants to know about.

Representative research photograph: Discussing How to Report Other Medicines and Products
Photo: Bill Branson (Photographer) · License: Public domain · Cropped and resized.
Published
Updated

A participant may not fully understand which medicines or products the study team wants to know about. They might omit something used occasionally or obtained without a prescription because it seems unimportant. The explanation should support accurate reporting for authorized assessment rather than independently label products safe or unsafe.

Define the workflow

Explain the requested changes and reporting period through the approved study process. A coordinator should not advise someone to stop existing treatment or start another product. If information is unclear, arrange suitable clarification for investigator review instead of creating a record through guesses.

Worked example

For example, a person lists regular prescriptions but does not think an occasional herbal product counts as medicine. During the appropriate discussion, staff clarify which product information the study considers. Packaging details can be shared through a suitable channel; staff should not enter a similarly named product without confirming what was used.

Practical checks

  • Explain the question’s scope using ordinary examples and check the person’s understanding.
  • Seek suitable clarification when product names or use details are uncertain rather than guessing.
  • Refer new use or clinical questions to the appropriate investigator for assessment.

Decision and boundaries

A good discussion preserves both the actual information reported and unresolved uncertainty. Do not blame someone for mentioning a change late; authorized staff assess safety and data implications. This operational approach is not advice to use, stop or alter any product. Medical decisions belong with the person’s appropriate healthcare team.

Frequently asked questions

Should nonprescription products be mentioned?
The authorized team should explain the information required so participants are not forced to guess whether a product matters.
Can a coordinator decide that a product is acceptable?
They should not make clinical judgments beyond their role and competence; refer assessment to the investigator or relevant healthcare professional.

Sources

  1. EMA — ICH E6 Good Clinical Practice
  2. WHO — Guidance for best practices for clinical trials